cilengitide has been researched along with B16 Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, G; Jin, Y; Liu, B; Liu, C; Pan, X; Yi, M; Yuan, X | 1 |
| Ding, Y; Lu, W; Tang, Y; Tao, X; Zhu, X | 1 |
| Cheresh, DA; Gillies, SD; Jonczyk, A; Lode, HN; Moehler, T; Reisfeld, RA; Xiang, R | 1 |
3 other study(ies) available for cilengitide and B16 Melanoma
| Article | Year |
|---|---|
Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
Topics: Animals; Apoptosis; B7-H1 Antigen; Cell Survival; Female; Immunohistochemistry; Integrin alphaVbeta3; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Skin Neoplasms; Snake Venoms | 2022 |
Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Integrin beta3; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplastic Stem Cells; Phenotype; Signal Transduction; Snake Venoms; Xenograft Model Antitumor Assays | 2019 |
Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
Topics: Animals; Antigens, CD; Colonic Neoplasms; Humans; Immunotherapy; Immunotoxins; Integrin alphaV; Interleukin-2; Melanoma, Experimental; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Neuroblastoma; Peptides, Cyclic; Receptors, Vitronectin; Recombinant Fusion Proteins; Snake Venoms; Tumor Cells, Cultured | 1999 |